Expert review of clinical immunology · 2025
Immune therapies for alopecia areata: evidence and new perspectives.
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lai Hui-Jun, Ye Zhi-Ming, Chen Si-Qi, McElwee Kevin J, Guo Hong-Wei
Аннотация
INTRODUCTION: Alopecia areata (AA) is an autoimmune non-scarring hair loss that involves collapse of hair follicle immune privilege. Genetic susceptibility, environmental stressors, and aberrant interaction between dendritic cells, CD4+ and CD8+ lymphocytes, drives follicular destruction and disrupts hair cycling. Pro-inflammatory cytokines, including IL-15 and IFNγ, and downstream JAK-STAT pathway activation, are central to disease progression.
AREAS COVERED: Though variably effective, conventional treatments including corticosteroids, contact sensitizers, phototherapy, and systemic immunosuppressants remain standard therapeutic approaches for AA in many clinics. However, insights into Th1, Th2, and Th17 cell activity, along with the cytokine signals involved (IFNγ, IL-15, IL-4/13, IL-17/23), and an emerging understanding of immune checkpoints in AA (PD-1/PD-L1, CD28/CD80/CD86/CTLA4, OX40/OX40L), are shaping the clinical investigation of new AA treatments; particularly JAK inhibitors and biologics targeting specific signaling pathways.
EXPERT OPINION: Heterogeneity in AA clinical presentation, molecular pathogenesis, and variable treatment responses suggests a biomarker-driven patient stratification system is needed to optimize drug selection, reduce trial-and-error therapy, and minimize side-effect risk. In the longer term, approaches that couple rapid immunosuppression with strategies to regenerate follicular immune privilege and tolerize autoreactive memory T cells are likely to shift AA therapeutic approaches away from chronic immune suppression toward true disease-modifying or curative interventions.
AREAS COVERED: Though variably effective, conventional treatments including corticosteroids, contact sensitizers, phototherapy, and systemic immunosuppressants remain standard therapeutic approaches for AA in many clinics. However, insights into Th1, Th2, and Th17 cell activity, along with the cytokine signals involved (IFNγ, IL-15, IL-4/13, IL-17/23), and an emerging understanding of immune checkpoints in AA (PD-1/PD-L1, CD28/CD80/CD86/CTLA4, OX40/OX40L), are shaping the clinical investigation of new AA treatments; particularly JAK inhibitors and biologics targeting specific signaling pathways.
EXPERT OPINION: Heterogeneity in AA clinical presentation, molecular pathogenesis, and variable treatment responses suggests a biomarker-driven patient stratification system is needed to optimize drug selection, reduce trial-and-error therapy, and minimize side-effect risk. In the longer term, approaches that couple rapid immunosuppression with strategies to regenerate follicular immune privilege and tolerize autoreactive memory T cells are likely to shift AA therapeutic approaches away from chronic immune suppression toward true disease-modifying or curative interventions.